Evo Fund Cuts Stake in Delta-Fly Pharma (4598) to 41.97% | Large Shareholding Report

A large shareholding report (EDINET filing) reveals that Evo Fund reduced its stake in Delta-Fly Pharma (4598) to 41.97%. The filer is an event-driven investment fund under the Evolution Japan umbrella. The company develops novel anti-cancer drug candidates using proprietary modular drug discovery technology and licenses development and marketing rights to pharmaceutical companies. Evo Fund's 41.97% ownership positions it as a controlling shareholder. The fund held 43.2% as of August 17, marking a reduction of 1.23 percentage points over just eleven days.

Staged Portfolio Reduction Over Eleven Days

Evo Fund's first large shareholding report for Delta-Fly Pharma was filed on August 17 at 43.2%, and this current filing on August 28 shows the 1.23 percentage point decline. The estimated sale proceeds of ¥20 million were derived from the closing price of 103 yen on the reporting date. This pattern indicates staged position reduction rather than a single transaction.

Commanding Shareholder Position Relative to Other Investors

When compared to other disclosed shareholders, Evo Fund's over-40% ownership stands in a different category entirely. Individual investor Kiyoshi Ejima holds 6.18%, SBI Securities holds 4.99%, and Morgan Stanley MUFG Securities holds 3.9%. Each represents a fraction of Evo Fund's stake. The fund maintains overwhelming majority ownership in Delta-Fly Pharma's shareholder base.

Diversified Industry Allocation Across 36 Holdings

Evo Fund held large positions in at least 36 companies as of this reporting date, with wide sectoral dispersion. Top holdings included Pixela Corporation in electrical machinery (60.71%), ANAHD in retail (54.95%), Bitcoin Japan in wholesale distribution (49.54%), Kaihan in retail (45.85%), and Ortho Plus in information and communications (42.58%). This lack of industry concentration reflects the fund's event-driven mandate, where investment opportunities are identified based on specific corporate catalysts such as regulatory approvals or business partnerships rather than sector themes.

Stock Trading Near 52-Week Lows

Delta-Fly Pharma traded at PBR 3.63 on the reporting date, with its price positioned at the first percentile of its 52-week range. This indicates near-trough valuations within the recent trading band. For bioventure companies whose share prices are sensitive to pipeline progress and partnership announcements, this level may reflect recent disappointments or market repricing of development prospects.

*Speculation: Evo Fund's expedited 1.23 percentage point reduction within eleven days may signal a shift in investment stance tied to developments in the anti-cancer drug pipeline or changes in partnership negotiations aligned with the fund's event-driven strategy.